Looking for a career in health economics and real-world evidence (RWE)? Check out the latest job openings in the pharmaceutical industry. There are many new opportunities available for RWE analysts, real-world evidence scientists, RWE managers, and real-world evidence market access managers in both pharmaceutical and life science consulting companies.
New health economist RWE jobs are added daily. Stay up to date and sign up for the free Boletín de Empleos de Economía de la Salud.
Petaling Jaya, Malaysia. The Principal Real World Evidence (RWE) Research Analyst is responsible for the scientific and methodological aspects of all RWE projects as well as providing guidance for other members of the team. Your Responsibilities: Your responsibilities include, but not limited to:• Produce analytic deliverables, including full study reports for RWE or observational database analyses projects.• Support project management … Read more
Oslo, Norway. Empower Teva’s Norwegian business forward by spearheading the development and execution of strategic market access (MA) initiatives. Drive successful pricing aligned with Teva’s overall strategy, navigate health technology assessment (HTA) processes to ensure optimal recommendations and implementation, enhance the MA and health economics expertise of the business unit lead, develop market access tools for existing and future launch … Read more
Tokyo, Japan. lDepartment functions: •IQVIA‘s core assets are medical big data and post-marketing observational research of innovative new drugs using technology. Evidence generation such as a> research PromoteHealth Economics & Outcome Research (HEOR), PMS. lBusiness content: Use •RealWorldEvidence(RWES) management of multiple projects, leading project teams and team participation in other areas with RWES in practice. •Achieve the project goals based … Read more
Cambridge, MA, US. The Associate Director, Epidemiology and RWE Sciences will support pre- and post-launch evidence generating activities across entire product portfolios within a Therapeutic Area. The role will be responsible for helping map out integrated evidence generation activities for a product and then designing, reviewing and supporting the execution of evidence generating activities using primary and secondary data, as … Read more
Beijing / Shanghai, China. RWE is increasingly important in China. Takeda China Medical has conducted several real-world studies (RWS). We hope the candidate provides HEOR&RWE and TAs with their experience and technical support. Key roles & responsibilities of Accelerator: 1. To learn China’s RWD resources and RWE development (overall picture such as Data status).2. To share RWE experience of candidate’s … Read more
US. The Sr. Manager, Health Economics and Outcomes Research (HEOR) & Real-World Evidence will be responsible for supporting the development and execution of global HEOR and RWE activities to support the Binding Site’s existing portfolio and pipeline products. This individual will play a key role in developing and executing HEOR/RWE strategies and will also assume a critical leadership role in … Read more
Raritan, NJ, US. The Global Commercial Strategy Organization is recruiting for a Director, Global Real World Evidence (RWE) Data Science Analytics in Global Commercial Data Science (GCDS). The position is based in Raritan, NJ and will require up to 25% travel. The Director Global RWE Data Science Analytics will lead the execution of industry leading RWE solutions across the GCDS … Read more
West Chester, PA US. The Associate Director, Real World Evidence Strategy is responsible for assessment of data needs/gaps, and identifying potential opportunities of using real world data to support all phases of drug development and commercial opportunities at Teva. Key activities include but are not limited to proactive identification and recommendation of new RWD sources and developing the road map … Read more
Seoul, South Korea. Works directly with clients to provide value added input, to develop business opportunities that will lead to additional starbursts and to deliver projects built around strategic issues. Has responsibility for ensuring delivery of high levels of client satisfaction. Typically works within a specific CoE area but may have responsibility across multiple expertise areas and/or clients. Meets or … Read more
Munich, Germany. We are seeking highly qualified candidates to fill the position: Global Oncology HEOR & RWE, Senior Manager (m/f/x). The Senior Manager, Global Health Economics Outcomes Research (HEOR) and Real World Evidence (RWE) reports to the Director Global HEOR ENHERTU leader and will work cross-functionally to implement HEOR and evidence generation projects. The person will work with other teams … Read more
Amsterdam, Netherlands. Ter versterking van ons team van consultants zijn wij op zoek naar een Healthcare consulent met expertise in Market Access in Nederland . Het team bestaat uit professionals met verschillende achtergronden en expertises, zoals: HTA, epidemiologie en market access. Met onze multidimensionale oplossingen en aanbiedingen zijn we toegewijd om de gezondheidszorg vooruit te helpen. Om onze bijdrage aan … Read more
London, UK. As part of the wider Real-World Evidence (RWE) team Lumanity is currently building a RWE Data Luminary Consulting Practice. This practice has been started as our clients have unique challenges which require RWE. For example, understanding treatment patterns/patient journeys, drug utilization studies, effectiveness of standard of care/generating synthetic controls, outcomes research, cost of illness, burden of disease, and … Read more
Seoul, South Korea. Responsibilities: • Carry out work relating to the HEOR business areas (longitudinal retrospective study using internal or external big data, longitudinal prospective observational study, cross-sectional survey of patients/healthcare provider/or payers, patient reported outcome report, etc). • Work with supervision, indepently and/or as part of a project team on defined tasks. • Involve in business development/internal initiatives i.e. … Read more
Tips and tricks to improve your CV and boost your health economics career. Are you tired of submitting countless job applications and never hearing back? Have you ever wondered why some job-seeking health economists seem to have all the luck? The answer is simple – they know how to create a winning CV that gets them hired. If you want … Read more
Real-world evidence (RWE) has become an increasingly important aspect of health economics research in recent years. It provides a comprehensive and in-depth understanding of how different health interventions work in real-world settings.
Real-world evidence (RWE) is defined as data collected from sources other than traditional randomized controlled trials (RCTs). These data come from a variety of sources, including electronic health records (EHRs), claims databases, registries, patient-reported outcomes (PROs), and surveys.
RWE allows researchers to evaluate the effectiveness, safety, and cost-effectiveness of health interventions in real-world settings. This is important because RCTs often have strict inclusion and exclusion criteria, which means that the results may not be generalizable to real-world populations.
RWE is becoming increasingly important in health economics because it provides a more complete picture of the effectiveness and safety of health interventions. By using RWE, researchers can evaluate how interventions work in a variety of settings and patient populations, which can help inform clinical practice and policy decisions.
RWE can also be used to conduct cost-effectiveness analyses, which help policymakers determine the value of health interventions. Cost-effectiveness analyses compare the costs and benefits of different health interventions, taking into account the costs of the intervention as well as the costs of any adverse events or complications that may occur.
RCTs are considered the gold standard for evaluating the effectiveness and safety of health interventions. However, there are several key differences between RWE and RCTs.
RCTs are conducted under controlled conditions and have strict inclusion and exclusion criteria, which means that the results may not be generalizable to real-world populations. RWE, on the other hand, is collected from a variety of sources and reflects the real-world experiences of patients.
RCTs also tend to be shorter in duration than RWE studies, which means that they may not capture the long-term effects of health interventions. RWE studies, on the other hand, can provide information on the long-term effectiveness and safety of interventions.
There are several methods of collecting RWE, including:
Electronic Health Records (EHRs)
EHRs are digital records of patient health information that are maintained by healthcare providers. EHRs can provide a wealth of information on patient demographics, diagnoses, treatments, and outcomes.
Claims Databases
Claims databases contain information on healthcare services and medications that are billed to insurance providers. Claims data can provide information on healthcare utilization, costs, and outcomes.
Registries
Registries are databases that collect information on specific diseases or health conditions. They can provide valuable information on disease prevalence, treatment patterns, and outcomes.
Patient-Reported Outcomes (PROs)
PROs are questionnaires or surveys completed by patients that assess their health status, symptoms, and quality of life. PROs can provide information on patient preferences and experiences with different interventions.
Surveys
Surveys can be used to collect information on patient demographics, health behaviors, and healthcare utilization. They can also be used to assess patient preferences and satisfaction with different interventions.
There are several advantages of using RWE in health economics research, including:
There are several challenges and limitations to using RWE in health economics research, including:
RWE has several applications in health economics research, including:
Health Technology Assessment
Health technology assessment (HTA) is a process that evaluates the clinical effectiveness, safety, and cost-effectiveness of new health technologies. RWE can be used in HTA to provide information on the real-world effectiveness and safety of interventions.
Comparative Effectiveness Research
Comparative effectiveness research (CER) compares the effectiveness of different interventions for the same health condition. RWE can be used in CER to compare the effectiveness of interventions in different patient populations and settings.
Post-Marketing Surveillance
Post-marketing surveillance is the process of monitoring the safety and effectiveness of new drugs and medical devices after they have been approved for use. RWE can be used in post-marketing surveillance to monitor the long-term safety and effectiveness of interventions.
RWE is likely to become increasingly important in health economics research in the future. Advances in technology and data analytics are making it easier to collect and analyze RWE, and policymakers are recognizing the importance of using RWE to inform clinical practice and policy decisions.
